Thermo Fisher Scientific Stock Berne S.E.
Equities
TFS
US8835561023
Advanced Medical Equipment & Technology
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
514.5 CHF | -0.35% |
|
-0.35% | +19.58% |
Sales 2024 * | 43.01B 38.55B | Sales 2025 * | 46.04B 41.26B | Capitalization | 205B 184B |
---|---|---|---|---|---|
Net income 2024 * | 6.18B 5.54B | Net income 2025 * | 6.96B 6.24B | EV / Sales 2024 * | 5.3 x |
Net Debt 2024 * | 23.2B 20.79B | Net Debt 2025 * | 19.14B 17.15B | EV / Sales 2025 * | 4.87 x |
P/E ratio 2024 * |
33.5
x | P/E ratio 2025 * |
28.8
x | Employees | - |
Yield 2024 * |
0.28% | Yield 2025 * |
0.3% | Free-Float | 86.04% |
Latest transcript on Thermo Fisher Scientific
1 day | -0.35% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Casper
CEO | Chief Executive Officer | 56 | 01-10-31 |
Director of Finance/CFO | 57 | 01-05-31 | |
Ryan Snyder
CTO | Chief Tech/Sci/R&D Officer | - | 18-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marc Casper
CEO | Chief Executive Officer | 56 | 01-10-31 |
C. Harris
BRD | Director/Board Member | 67 | 12-03-29 |
Ruby Chandy
BRD | Director/Board Member | 62 | 22-02-28 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.45% | 179B | |
+31.46% | 158B | |
+33.00% | 113B | |
+4.87% | 64.93B | |
+21.77% | 56.51B | |
-2.92% | 46.36B | |
-5.91% | 37.07B | |
+3.39% | 36.12B | |
+16.14% | 28.25B |
- Stock Market
- Equities
- TMO Stock
- TFS Stock